Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Technology Transfer topic
No spam. Unsubscribe anytime.
Iowa State faculty presenter describes resonance-sensor startup and applications in cell and gene therapy manufacturing
Summary
Associate Professor Nigel Ruehl summarized research-to-market pathways for resonance sensors and enzyme detection technologies developed at Iowa State; he described a partnership with Wilson Wolf for wireless sensors to time cell-harvests in cell and gene therapy manufacturing and noted commercialization progress.
Associate Professor Nigel Ruehl of Iowa State University presented to the Board of Regents on April 24 about research projects that have progressed into commercial ventures, focusing on resonance sensors that can wirelessly monitor cell culture and support manufacturing for cell and gene therapies.
Ruehl described resonance sensors as radio-frequency coils sensitive to changes in permittivity; the sensors are paired with responsive surface chemistries to detect biological changes. He said early industry engagement through a National Science Foundation award allowed the research team to explore multiple applications—from sweat monitoring for firefighters to smart bandages and soil moisture sensing—and that a side project matured into a marketable product through further SBIR funding and customer-discovery work.
Ruehl said the team’s most promising commercial application is in cell and gene therapy manufacturing. In that workflow, engineered patient cells must be expanded in vessels to a target dose; growth rates vary by donor and “timing the harvest” matters. He said the resonance sensor can monitor growth trajectories in real time and “time the perfect point of harvest,” reducing manual sampling and helping standardize production. Ruehl said design and prototype work is centered in Ames while scale manufacturing is done with partners; he said the product was expected to be product-ready by the end of the year or early next year and that regulatory work was underway.
Ruehl also summarized other ventures that spun from lab work: a company using cell-free expression for rapid protein prototyping that later pivoted into drug-discovery work and was acquired, and a company using nano-sensors for rapid enzyme detection that works with customers including local company Kemin. He emphasized student training and tech-transfer pathways as key outcomes of the university-supported commercialization efforts.
